{"product_id":"evgn-pestle-analysis","title":"(EVGN) Evogene Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Evogene Ltd. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces may impact the company and is useful for investors, strategists, and researchers. The page contains a real preview\/sample of the report so you can judge style and depth—purchase the full version to receive the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e4 operating geographies: Israel, United States, Brazil and other markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. operates across 4 geographies, including Israel, the United States, Brazil and other markets, so it faces 3 different policy tracks: biotech, agriculture and healthcare. A rule change in one market can delay trial approvals, slow partnerships and push out commercialization dates. Cross-border work also raises exposure to sanctions, trade frictions and supply-chain shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1999-founded Israeli company with life-science R\u0026amp;D exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIsrael’s innovation policy supports Evogene Ltd.’s R\u0026amp;D model: OECD data show Israel spends about 6.3% of GDP on R\u0026amp;D, the highest in the group. Tax credits, grants, and government-backed research support can lower development costs, but the country’s security risks can still disrupt staffing, logistics, and lab continuity. For an R\u0026amp;D-heavy company, execution risk matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural biotech linked to public food-security policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational agriculture policy drives demand for Evogene Ltd.’s seed traits, crop chemicals and biologicals because yield and resilience targets shape what farmers buy. OECD says farm support across 54 countries reached about USD 842 billion in 2023, so public funding can move markets fast. If food-security rules and procurement favor sustainable inputs, Evogene’s products can gain faster adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-driven model with BASF, Corteva and Bayer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd.'s BASF, Corteva and Bayer partnerships sit in markets shaped by farm rules, trade limits and licensing laws across many countries. Political shifts can change who can sell, where joint products can launch, and how much scope each partner gets. The model works best when regulation stays stable; in 2025, global agri trade still faced new tariff and biotech-review friction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePolicy can narrow licensing rights.\u003c\/li\u003e\n\u003cli\u003eTrade rules can block market access.\u003c\/li\u003e\n\u003cli\u003eStable regulation supports partner ROI.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical cannabis activity in regulated markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCannabis stays politically sensitive and tightly controlled, so a shift in government stance can change licensing, distribution, and product acceptance fast. That creates both upside and policy risk for Evogene Ltd. Canonic and Cannbit collaborations, especially where regulators can pause or widen access overnight.\u003c\/p\u003e\n\u003cp\u003eIn regulated markets such as Israel and Germany, market access depends on permits, GMP compliance, and import rules, so approvals are never fixed. A friendlier policy can speed rollout and revenue, but a stricter one can delay launches and cut partner sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePolicy shifts can reprice access fast.\u003c\/li\u003e\n\u003cli\u003eLicenses and distribution are government-led.\u003c\/li\u003e\n\u003cli\u003eCanonic and Cannbit face both upside and risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene Faces Policy-Driven Growth Risks Across Global Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. is highly exposed to policy shifts because its R\u0026amp;D, agri-tech, and cannabis work depends on permits, trade rules, and product approvals across Israel, the United States, Brazil, and Europe. Israel’s 6.3% R\u0026amp;D spend supports its innovation base, but security and regulatory shocks can still delay labs, trials, and partner launches. In 2025, agri trade and biotech review friction kept market access uneven.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael R\u0026amp;D intensity\u003c\/td\u003e\n\u003ctd\u003e6.3% of GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal farm support\u003c\/td\u003e\n\u003ctd\u003eUSD 842bn in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey risk\u003c\/td\u003e\n\u003ctd\u003eApprovals and licenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes how political, economic, social, technological, environmental, and legal forces shape Evogene Ltd.’s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, organized Evogene Ltd. PESTLE snapshot that makes external risks and opportunities easy to review at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, patents, company filings, and peer‑reviewed studies to fast‑track due diligence and verify Evogene’s market, pricing, and competitive assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-intensive business model across 3 divisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene’s R\u0026amp;D-heavy model across 3 divisions keeps cash tied up for years, so spending often comes before sales. In 2025, that means funding access and partner cash support matter more than near-term margin, because revenue can lag scientific validation and create working-capital strain. \u003c\/p\u003e\n\u003cp\u003eEach division needs long trials, data, and regulatory steps, so the cost base stays high even when sales are uneven. That makes liquidity the key economic driver: without fresh capital or upfront partner payments, project timing can slip and burn rates rise. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgriculture demand tied to farmer spending cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s seed traits, biologicals, and crop chemicals sell best when farm income and input budgets are healthy. USDA’s 2025 U.S. net farm income is forecast at $180.1 billion, but crop cash receipts are down 2.1%, so farmers stay selective. Corn, soybean, wheat, rice, and cotton prices still steer adoption, and weak margins usually slow buying.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to USD, ILS and BRL currency movements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s mix in Israel, the U.S. and Brazil leaves it exposed to USD, ILS and BRL swings; in 2025, USD\/ILS traded roughly 3.5-3.8 and USD\/BRL about 5.0-6.0, so even small moves can shift reported revenue and R\u0026amp;D spend. A stronger shekel lifts Israel-based costs in USD terms, while a weaker real can help local expenses but can also distort partner economics in Brazil. For an international R\u0026amp;D and commercialization model, FX can move margins faster than sales do.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing and collaboration revenue dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd. relies heavily on licensing and collaboration income, so milestone fees, royalties, and partner-funded R\u0026amp;D are a key cash-flow buffer. This makes income less tied to product sales, but it also leaves near-term visibility exposed when partner programs slip. For platform firms, slower partner timelines usually mean delayed revenue recognition and weaker quarter-to-quarter predictability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones support cash flow.\u003c\/li\u003e\n\u003cli\u003eRoyalties depend on partner launches.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D funding can offset burn.\u003c\/li\u003e\n\u003cli\u003eDelays cut near-term visibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHuman health and cannabis markets are capital-sensitive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuman health and cannabis markets are capital-sensitive because microbiome therapies and medical cannabis need heavy clinical, regulatory, and launch spending before revenue starts. When risk appetite for speculative life-science assets tightens, valuations fall, follow-on funding gets harder, and Evogene Ltd. may have to slow expansion or accept more dilution. That makes cash runway and financing timing critical. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upfront R\u0026amp;D and approval costs\u003c\/li\u003e\n\u003cli\u003eValuation swings hit funding access\u003c\/li\u003e\n\u003cli\u003eTighter markets can slow expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene’s 2025 story: cash burn, farm income, and FX drive the outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene’s 2025 economics hinge on cash, not margin: R\u0026amp;D spend comes before sales, so funding and partner advances matter most. USDA’s 2025 U.S. net farm income is forecast at $180.1B, but crop cash receipts are down 2.1%, which can slow seed and biologicals adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 factor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS farm income\u003c\/td\u003e\n\u003ctd\u003e$180.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop cash receipts\u003c\/td\u003e\n\u003ctd\u003e-2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX risk\u003c\/td\u003e\n\u003ctd\u003eUSD\/ILS 3.5-3.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eUSD\/BRL near 5.0-6.0 also moves reported costs and partner economics, while slower partner timelines can delay milestone cash and raise burn.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eEvogene Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Evogene Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal food-security demand across staple crops\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal food-security pressure keeps demand high for corn, soybean, wheat, rice and cotton, and FAO’s 2025 outlook still points to more than 2.8 billion tons of world cereal output needs. Farmers and governments want higher yields from less land, so resilient seed traits matter more. That supports Evogene Ltd.’s agriculture pipeline, especially tools that hold up in heat, drought and disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising preference for sustainable farm inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStakeholders are shifting toward biological and lower-residue inputs; biocontrols still make up only about 5% of global crop protection sales, so adoption has room to run. Consumer pressure on food safety and cleaner supply chains is pushing growers and retailers toward greener tools, which supports Evogene’s biologicals and seed-trait pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic acceptance challenges for biotech and cannabis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic acceptance still limits Evogene Ltd.'s biotech and cannabis markets: many consumers stay wary of GM crops and cannabis products until they see safety data, clear labeling, and third-party proof. In the U.S., the FDA has approved only 2 cannabis-derived medicines, which shows how slowly trust builds even after science advances. Adoption usually rises after regulatory green lights and strong real-world evidence of benefit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGrowing awareness of microbiome-based health solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInterest in gut health, immune health, and antimicrobial resistance is rising, and WHO says antimicrobial resistance caused 1.27 million deaths in 2019. That shift makes patients and clinicians more open to targeted biological treatments, which supports Evogene Ltd.'s human health programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore demand for gut and immune solutions\u003c\/li\u003e\n\u003cli\u003eHigher acceptance of biologic treatments\u003c\/li\u003e\n\u003cli\u003eAMR keeps the issue urgent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstitutional demand for reduced antibiotic and chemical use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealth and agriculture systems are under pressure to cut antibiotic and pesticide use: WHO linked antimicrobial resistance to 1.27 million deaths in 2019, while the EU’s Farm to Fork plan targets a 50% cut in pesticide risk by 2030. Social concern over resistance, residues, and soil harm is shifting buyer demand toward cleaner inputs.\u003c\/p\u003e\n\u003cp\u003eEvogene Ltd.’s biological and microbiome platforms fit this shift, since they aim to replace or reduce chemical dependence in crop protection and productivity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower residue and resistance risk\u003c\/li\u003e\n\u003cli\u003eSupports demand for bio-based inputs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCleaner crop inputs and trust trends favor Evogene’s biologicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociology favors Evogene Ltd. as farmers and buyers push for cleaner, lower-residue inputs; biocontrols are still about 5% of global crop-protection sales, so adoption can keep rising. Public concern over food safety and antibiotic resistance also supports its biological platforms. Trust still matters most, so proof from field results and labels will drive uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiocontrol share\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMR deaths\u003c\/td\u003e\n\u003ctd\u003e1.27M in 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU pesticide cut target\u003c\/td\u003e\n\u003ctd\u003e50% by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCPB platform: Computational Predictive Biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene’s CPB platform is a proprietary predictive biology engine that uses computational tools to identify and guide product discovery. It supports faster screening, broader scale, and lower discovery risk by focusing R\u0026amp;D on the most promising biological targets. This matters for Evogene because it helps turn large data sets into more selective pipeline decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI and big-data analytics in life-science discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. depends on AI and large biological datasets to screen microbes, small molecules, and genetic components faster than lab-only workflows. In 2025, that data edge stayed central as the company pushed model-driven discovery across its three core tech engines. \u003c\/p\u003e\n\u003cp\u003eIts advantage rests on better prediction quality, so each new dataset and validated hit improves screening speed and hit rates. If model accuracy slips, the edge narrows fast in a field where rivals also use machine learning. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 core innovation areas: microbes, small molecules, genetic components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.'s three core innovation areas—microbes, small molecules, and genetic components—widen its addressable market across agriculture, human health, and industrial uses. This mix also lowers reliance on any one product format, which can smooth revenue risk as programs shift from discovery to commercial use. The multi-platform model gives Evogene more shots at value creation, but execution across three science stacks also raises R\u0026amp;D complexity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital discovery for seed traits and biological products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital discovery lets Evogene Ltd. screen millions of trait and biology candidates in silico before costly lab and field work. That cuts cycle time and lifts hit rates, which matters because a single missed season can delay commercialization by 12 months or more.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrioritize faster, cheaper candidates first.\u003c\/li\u003e\n\u003cli\u003eReduce wet-lab and field-trial load.\u003c\/li\u003e\n\u003cli\u003eSpeed matters in short crop windows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData-driven microbiome and castor-bean programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd.’s microbiome and castor-bean work depends on specialized datasets, and the edge comes from linking wet-lab tests with computational prediction. That matters because castor oil contains about 90% ricinoleic acid, so small trait gains can matter in both health and industrial uses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLab validation must confirm model hits.\u003c\/li\u003e\n\u003cli\u003eShared data can speed pipeline generation.\u003c\/li\u003e\n\u003cli\u003ePlatform strength can lower repeat R\u0026amp;D costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene’s AI Edge: Faster Discovery, Lower R\u0026amp;D Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene’s tech edge in 2025–2026 rests on CPB, an AI biology engine that narrows discovery faster than lab-only work. Its three stacks—microbes, small molecules, and genetic components—keep data reuse high and spread R\u0026amp;D risk. The key test is model accuracy: better hits cut wet-lab cost and speed decisions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore tech\u003c\/td\u003e\n\u003ctd\u003eCPB AI platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform stacks\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCastor oil ricinoleic acid\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech regulation across the US, Israel and Brazil\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. faces three different rule sets in the US, Israel and Brazil for R\u0026amp;D, field trials and sales, so one program can need three compliance paths. In Brazil, CTNBio reviews GMO field work and can take up to 90 days for some determinations, while US FDA\/USDA and Israel’s health, agriculture and environmental rules can shift launch timing. That timing risk can move partner milestones and cash receipts. Evogene needs one compliance system that tracks all three legal regimes at once.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP protection for platform and product discoveries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s value depends on proprietary algorithms, biological know-how, and licensed outputs, so IP protection is a core legal risk. Strong patents and trade secrets help defend partner deals and royalty streams, while weak protection can quickly erode pricing power and commercial leverage.\u003c\/p\u003e\n\u003cp\u003eThis matters because the platform is built on hard-to-copy discovery assets, not just physical products. If rivals can replicate key methods or outputs, Evogene Ltd. loses bargaining strength in licensing talks and could face lower margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing agreements with BASF, Corteva and Bayer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s licensing deals with BASF, Corteva and Bayer depend on tight control of rights, milestones and royalty terms. In 2025, this matters even more because platform-based revenue only scales when each partner’s field, territory and IP scope are clear. Any legal dispute or vague language can delay milestone cash and push royalties out.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical cannabis compliance via Canonic and Cannbit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2026, medical cannabis still faces country-by-country licensing, GMP, and traceability rules, so Canonic and Cannbit need separate approvals for cultivation, processing, and distribution. Legal status can also shift by product class, with some markets allowing only prescription use, which slows rollout and raises compliance cost. For Evogene Ltd., that means expansion speed depends on local regulatory clearance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSeparate licenses in each market\u003c\/li\u003e\n\u003cli\u003eHigher quality and distribution costs\u003c\/li\u003e\n\u003cli\u003eProduct class rules can block expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHuman health programs subject to clinical and safety rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMicrobiome therapies and antimicrobial-resistant infection programs face strict clinical, safety, labeling, and claims rules, so Evogene Ltd. must prove efficacy and manage adverse-event risk before launch.\u003c\/p\u003e\n\u003cp\u003eIn the U.S., the FDA can block or delay commercialization if trial design, manufacturing, or product claims do not meet healthcare standards; this is especially critical for human health programs that need clear clinical proof.\u003c\/p\u003e\n\u003cp\u003eFor Evogene Ltd., weak regulatory compliance can turn promising science into a stalled asset, while strong data can support faster approvals and cleaner market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical trials must meet safety rules\u003c\/li\u003e\n\u003cli\u003eClaims need regulatory support\u003c\/li\u003e\n\u003cli\u003eLabeling is tightly controlled\u003c\/li\u003e\n\u003cli\u003eNoncompliance can stop launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene Faces Three-Layer Regulatory and IP Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. must clear different legal regimes in the US, Israel and Brazil for trials and sales, so one program can face three approval paths. Brazil’s CTNBio can take up to 90 days on some GMO decisions. IP protection is key: patents, trade secrets and tight license terms protect partner revenue and royalties. Medical cannabis and health programs still face strict local licensing and clinical rules.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrazil GMO review\u003c\/td\u003e\n\u003ctd\u003eUp to 90 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore markets\u003c\/td\u003e\n\u003ctd\u003eUS, Israel, Brazil\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey risk\u003c\/td\u003e\n\u003ctd\u003eIP and license disputes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth programs\u003c\/td\u003e\n\u003ctd\u003eStrict trial and labeling rules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate stress across corn, soybean, wheat, rice and cotton\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e2024 was the warmest year on record, about 1.55°C above pre-industrial levels, and heat, drought and storm swings hit corn, soybean, wheat, rice and cotton yields. This lifts demand for stress-tolerant crops and fits Evogene Ltd.'s pipeline focus on yield under harsh conditions. Climate risk also makes predictive breeding tools more valuable because they can shorten testing and target resilient traits faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower-chemical farming demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLower-chemical farming is gaining pressure as regulators and buyers push for less synthetic input use; the global biopesticides market is forecast to exceed $10 billion by 2027. Evogene Ltd. can benefit through biological products and precision traits that help cut spray volumes and improve crop resilience. That supports its crop-focused units by matching a clear shift in farm spending toward lower-toxicity tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoil, water and land-use constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. faces a market where agriculture uses about 70% of global freshwater withdrawals, and the UN says up to 40% of soil is degraded. That makes water-saving and soil-boosting products more valuable, especially in large-scale cropping. Resource-efficient traits can cut input use and help farms protect yields under tighter land-use limits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIndustrial applications tied to castor bean sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastor bean improvement can support renewable industrial feedstocks, especially as manufacturers cut fossil-based inputs. India still drives about 80% of global castor seed supply, so crop yield and oil quality gains matter for scale and supply risk. That can lift interest in Evogene Ltd.’s industrial segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRenewable feedstock demand is rising.\u003c\/li\u003e\n\u003cli\u003eSupplier sustainability is now a priority.\u003c\/li\u003e\n\u003cli\u003eCastor genetics can improve supply.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiosafety and ecological impact scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd.’s biological and genetically guided products face tight biosafety checks, because regulators and customers want low ecological risk before deployment. In agri-biotech, field and environmental validation can stretch launch plans by 6-18 months, so approval speed matters. This scrutiny can slow time-to-market, but it also supports trust and adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow ecological risk is a buying filter.\u003c\/li\u003e\n\u003cli\u003eValidation can delay launch by months.\u003c\/li\u003e\n\u003cli\u003eResponsible deployment supports adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate Pressure Boosts Demand for Evogene’s Resilient Crop Traits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvironmental pressure is rising for Evogene Ltd.: 2024 was 1.55°C above pre-industrial levels, and heat, drought and floods are pushing demand for resilient crops and faster trait screening. Agriculture still uses about 70% of global freshwater, while up to 40% of soil is degraded, so water-saving and soil-health traits matter more. Low-chemical farming is also growing, with biopesticides forecast above $10 billion by 2027. Biosafety checks can slow launches by 6-18 months, but they also support trust.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003cth\u003eImpact on Evogene Ltd.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate stress\u003c\/td\u003e\n\u003ctd\u003e2024 +1.55°C\u003c\/td\u003e\n\u003ctd\u003eHigher demand for resilient traits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResource pressure\u003c\/td\u003e\n\u003ctd\u003e70% water, 40% soil degraded\u003c\/td\u003e\n\u003ctd\u003eStronger case for efficient crops\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234321277193,"sku":"evgn-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/evgn-pestle-analysis.webp?v=1785718200","url":"https:\/\/dcfanalyst.com\/products\/evgn-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}